Aura Biosciences (Aura Biosciences) Scaled Net Operating Assets : 0.10 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Aura Biosciences Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Aura Biosciences's operating assets for the quarter that ended in Mar. 2024 was $32.15 Mil. Aura Biosciences's operating liabilities for the quarter that ended in Mar. 2024 was $6.92 Mil. Aura Biosciences's Total Assets for the quarter that ended in Dec. 2023 was $255.08 Mil. Therefore, Aura Biosciences's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2024 was 0.10.

Aura Biosciences Scaled Net Operating Assets Historical Data

The historical data trend for Aura Biosciences's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aura Biosciences Scaled Net Operating Assets Chart

Aura Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Scaled Net Operating Assets

-3.23

0.05

0.19

0.17

0.09

Aura Biosciences Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Scaled Net Operating Assets	Get a 7-Day Free Trial												0.12	0.12	0.12	0.11	0.10

Competitive Comparison of Aura Biosciences's Scaled Net Operating Assets

For the Biotechnology subindustry, Aura Biosciences's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aura Biosciences's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aura Biosciences's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Aura Biosciences's Scaled Net Operating Assets falls into.

Aura Biosciences Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Aura Biosciences's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2023 )
=	(Operating Assets (A: Dec. 2023 )	-	Operating Liabilities (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2022 )
=	(28.925	-	9.67)	/	223.935
=	0.09

where

	Operating Assets		(A: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	255.075	-	226.15
=	28.925

	Operating Liabilities		(A: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	29.227	-	16.87	-	2.687
=	9.67

Aura Biosciences's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2024 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Mar. 2024 )
=	(Operating Assets (Q: Mar. 2024 )	-	Operating Liabilities (Q: Mar. 2024 ))	/	Total Assets (Q: Dec. 2023 )
=	(32.151	-	6.922)	/	255.075
=	0.10

where

	Operating Assets		(Q: Mar. 2024 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	235.025	-	202.874
=	32.151

	Operating Liabilities		(Q: Mar. 2024 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	26.242	-	16.579	-	2.741
=	6.922

Aura Biosciences Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Aura Biosciences's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Aura Biosciences (Aura Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aura Biosciences Inc (NAS:AURA) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

85 Bolton Street, Cambridge, MA, USA, 02140

Website

https://www.aurabiosciences.com

Aura Biosciences Inc is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy cancer cells selectively while activating the immune system to create long-lasting anti-tumor immunity.

Executives

Matrix Capital Management Company, Lp	10 percent owner	1000 WINTER STREET, C/O MATRIX CAPITAL MANAGEMENT, WALTHAM MA 02451
David Michael Johnson	director	C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Julie B Feder	officer: Chief Financial Officer	C/O VERASTEM, INC., 117 KENDRICK STREET, SUITE 500, NEEDHAM MA 02494
De Los Pinos Elisabet	director, officer: Chief Executive Officer	C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140
Janet Jill Hopkins	officer: See Remarks	C/O AURA BIOSCIENCES, INC., 80 GUEST STREET, BOSTON MA 01235
Cadmus Rich	officer: See Remarks	C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140
Rosch Mark De	officer: Chief Operating Officer	C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140
Medicxi Ventures Management (jersey) Ltd	10 percent owner	C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG
Medicxi Growth I Lp	10 percent owner	C/O ELIAN FUND SERVICES (JERSEY) LIMITED, 44 ESPLANADE, ST HELIER Y9 JE4 9WG
Giovanni Mariggi	director	C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140
Medicxi Growth I Gp Ltd	10 percent owner	C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG
Medicxi Growth Co-invest I Lp	10 percent owner	C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG
David E. Goel	10 percent owner	C/O MATRIX CAPITAL MANAGEMENT CO., LP, 1000 WINTER STREET, SUITE 4500, WALTHAM MA 02451
Karan S. Takhar	director	C/O ZENTALIS PHARMACEUTICALS,INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Antony C. Mattessich	director	C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730